GlassScriptPhysician profile
Lynelle Endsley
NPI 1609262526
$1,906.24
in general payments reported to CMS, 2019-2025
12 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,528 · 2023: $94.66 · 2024: $18.51 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $378.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $739.13 | 2021-2025 | General - Pain Management |
| Abbott Laboratories | $334.35 | 2021-2023 | Proclaim |
| Abbvie INC. | $247.69 | 2021 | |
| Nalu Medical, INC. | $162.69 | 2025 | Nalu Neurostimulation System |
| Biodelivery Sciences International, INC. | $129.84 | 2021 | |
| Collegium Pharmaceutical, INC. | $83.22 | 2021-2025 | Belbuca |
| Almatica Pharma LLC | $47.18 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $38.38 | 2021 | |
| Spr Therapeutics, INC | $35.92 | 2025 | Sprint Pns System |
| Stryker Corporation | $24.79 | 2025 | Optablate |
| Pfizer INC. | $18.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynelle Endsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.